GLP-1 Weight Loss in Newark, NJ: A 21.7% Uninsured Rate and a Brand-New Shortage Designation
Newark's 8.2-point obesity gap over New Jersey, a 21.7% uninsured rate, the January 2026 North Newark Primary Care HPSA, and two hospital programs with no published price.
Newark's adult obesity prevalence is 35.9% (CDC PLACES 2025 release, BRFSS 2023) 1 against New Jersey's 27.7% 2, an 8.2-point gap and the widest in this batch. The city's 317,303 residents sit inside the New York-Newark-Jersey City metro of 19,798,536 345.
The number that defines this page is coverage: 21.7% of Newark residents are uninsured, against a $58,490 median household income 6789. In January 2026 HRSA designated a brand-new Primary Care shortage area over the north side of the city 10.
Newark carries HRSA shortage designations at both the geographic and facility level. Two brand-new 2026 geographic HPSAs cover "North Newark": a Primary Care HPSA (ID 1342398978), designated 1/21/2026, scoring 13/26 with a 3,719:1 patient-to-provider ratio against a 3,500:1 goal, covering 154,066 residents across 46 census tracts (24.6% below poverty); and a Mental Health HPSA (ID 7342316983), designated 3/11/2026, scoring 19/25 with a 98,664:1 ratio against a 30,000:1 psychiatrist-population goal, covering 86,331 residents across 33 tracts (34.6% below poverty). Five Newark FQHCs also carry their own facility-level HPSA scores: City of Newark Dept. of Health (PC 15 / MH 23), Newark Community Health Centers Inc. (PC 15 / MH 22), Saint James Health Inc. (MH 22), Ironbound Community Health Center Inc. (MH 12), and a Rutgers NJMS-affiliated site (MH 17; its earlier PC HPSA was withdrawn in 2020). An older citywide "South Newark" geographic PC HPSA was withdrawn in 1995 and not replaced until the January 2026 North Newark designation.1011
Specialist access
HRSA does not track endocrinology or obesity medicine as a standalone shortage discipline, so there is no federal specialist-shortage score for Newark specifically. But the primary-care layer that normally screens, diagnoses, and refers patients into GLP-1 or specialist obesity care is itself newly shortage-designated: the North Newark Primary Care HPSA (154,066 residents, designated 1/21/2026) plus five separately shortage-scored FQHCs mean the referral pipeline into specialty endocrine/obesity care is constrained well upstream of any specialist's waiting room. In practice, specialist-level obesity and endocrine care in Newark runs through academic hospital systems — Rutgers NJMS/University Hospital and RWJBarnabas/Newark Beth Israel — rather than independent specialist practices.10
Medicaid coverage note
NJ FamilyCare (NJ Medicaid) is federally required to cover GLP-1s like semaglutide for type-2-diabetes indications under 42 U.S.C. §1396r-8(d)(2). That same federal statute explicitly allows states to exclude "agents used for weight loss" from mandatory coverage, so coverage for the obesity/weight-loss indication (Wegovy/Zepbound-style prescribing) — and any prior-authorization NJ FamilyCare attaches to it — is a state-discretionary policy question that could not be confirmed from a live NJ Medicaid PDL or policy document this session (njmmis.com's public page did not surface the PDL). Treat this as a data gap, not an asserted policy. This is the general pattern Astra's flat, insurance-independent national cash pricing is positioned against locally.15
Diabetes coverage is federally required; the weight-loss answer is not on the record
NJ FamilyCare is federally required to cover GLP-1s such as semaglutide for type 2 diabetes indications under 42 U.S.C. §1396r-8(d)(2) 15. That same statute explicitly allows states to exclude "agents used for weight loss" from mandatory coverage.
Whether New Jersey does exclude it, and what prior authorization it attaches, is a state-discretionary question that could not be confirmed from a live NJ Medicaid PDL or policy document this session, since njmmis.com's public page did not surface the PDL. That is recorded here as a data gap, not an asserted policy. In a city where more than one resident in five carries no insurance at all, the payer question is beside the point for a large share of the population.
What GLP-1 care costs in Newark today
RWJBarnabas Health's Newark Beth Israel Medical Center lists weight-loss and bariatric surgery as a service line at its Newark campus. The page names no GLP-1 medication and publishes no price for any weight-loss program, offering only a generic sitewide "Price Transparency" link 12.
University Hospital's Weight Management Center, affiliated with Rutgers NJMS, describes a multidisciplinary team with medical and surgical weight-loss tracks. No GLP-1 drug names and no self-pay pricing appear on the page 13. The national chains that do post transparent self-pay pricing, Genesis Lifestyle Medicine and Sōna MedSpa, operate no New Jersey location of any kind per their own directories, so no chain price can be cited as local to Newark 14.
Astra's price is published and flat everywhere it treats: $68/month for compounded semaglutide and $118/month for compounded tirzepatide, both on 12-month plans billed annually at $816 and $1,416. That is the same number in Newark as in every other state Astra serves, with no local rate and no consult required to see it.
The referral pipeline is constrained upstream of any specialist
Two brand-new 2026 geographic HPSAs cover "North Newark." The Primary Care designation (ID 1342398978, designated 1/21/2026) scores 13 of 26 with a 3,719:1 patient-to-provider ratio against a 3,500:1 goal, covering 154,066 residents across 46 census tracts where 24.6% live below poverty 10. The Mental Health designation (ID 7342316983, designated 3/11/2026) scores 19 of 25 with a 98,664:1 ratio against a 30,000:1 psychiatrist goal, covering 86,331 residents across 33 tracts at 34.6% below poverty 11. The city's earlier "South Newark" geographic designation was withdrawn in 1995 and nothing replaced it until this January 10.
Five Newark FQHCs carry their own facility scores: City of Newark Dept. of Health (Primary Care 15 / Mental Health 23), Newark Community Health Centers (15 / 22), Saint James Health (Mental Health 22), Ironbound Community Health Center (Mental Health 12), and a Rutgers NJMS-affiliated site (Mental Health 17), whose earlier Primary Care designation was withdrawn in 2020 1011.
HRSA does not track endocrinology as a discipline, but the layer that screens and refers patients into obesity care is itself newly designated as short. Specialist-level care here runs through Rutgers NJMS/University Hospital and RWJBarnabas/Newark Beth Israel rather than independent practices, which means the bottleneck sits well upstream of any specialist's waiting room. Telehealth starts at the prescriber instead. Astra serves all 50 states, including New Jersey.
Astra treats patients in New Jersey through state-licensed physicians.
Local options
RWJBarnabas Health – Newark Beth Israel Medical Center (Weight Loss & Bariatric Surgery) — Lists weight-loss/bariatric surgery as a service line at its Newark campus. The page names no GLP-1 medication (semaglutide/tirzepatide) and publishes no price for any weight-loss program — only a generic sitewide "Price Transparency" link. https://www.rwjbh.org/newark-beth-israel-medical-center/treatment-care/weight-loss-and-bariatric-surgery/(checked 2026-08-28)
University Hospital (Newark, NJ) – Weight Management Center — Describes the Rutgers NJMS-affiliated Weight Management Center's multidisciplinary team, offering both a medical (non-surgical) and a surgical weight-loss track. No GLP-1 drug names and no self-pay pricing appear on the page. https://www.uhnj.org/services/weight-management-center/(checked 2026-08-28)
National GLP-1/medspa chains checked for a Newark location (Genesis Lifestyle Medicine, Sōna MedSpa) — Both chains post transparent self-pay weight-loss pricing at their U.S. locations, but neither operates a New Jersey location of any kind — confirmed via their own location directories — so no chain pricing can be cited as local to Newark. https://www.sonamedspa.com/locations/(checked 2026-08-28)
Frequently asked questions
What is Newark's obesity rate compared to the rest of New Jersey?
35.9% of Newark adults have obesity (CDC PLACES, BRFSS 2023 place-level estimate) versus 27.7% statewide (CDC BRFSS, 2024 state-level estimate) — a gap of more than eight percentage points inside one of the wealthiest states in the country. The one-year offset between the city and state figures reflects CDC's release schedule (place-level data lags state-level by about a year), not a real trend difference.
Are there any weight-loss clinics in Newark that publish their GLP-1 prices?
Not that we found. We checked Newark Beth Israel Medical Center's Weight Loss & Bariatric Surgery program and University Hospital Newark's Weight Management Center directly — both list weight-loss services but neither names a GLP-1 medication or a price anywhere on their pages (checked 8/28/2026). Two national medspa chains that do post transparent pricing elsewhere, Genesis Lifestyle Medicine and Sōna MedSpa, confirmed via their own location directories that neither operates in New Jersey at all. Astra's $68/mo semaglutide and $118/mo tirzepatide (12-month plans) are the only published GLP-1 prices we could verify anywhere near Newark.
Is Astra cheaper in Newark than local options?
We can't run a full comparison, because no clinic in Newark — including its two major hospital-system weight-loss programs — publishes a self-pay GLP-1 price to compare against. What we can state plainly is Astra's own price, identical in Newark and everywhere else Astra serves: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans ($816 and $1,416 billed annually). Until a Newark provider publishes a verified price, Astra's is the only published number in this market.
Is Ozempic or Wegovy covered by NJ FamilyCare (Medicaid) for weight loss in Newark?
It depends on the indication. Federal law requires NJ FamilyCare to cover GLP-1s like semaglutide for a type-2-diabetes diagnosis, but that same law (42 U.S.C. §1396r-8(d)(2)) lets states exclude "agents used for weight loss" from mandatory coverage — so obesity-indication coverage for Wegovy- or Zepbound-style prescribing is a state policy choice. NJ FamilyCare's current prior-authorization policy wasn't available from a live public source this session, so confirm your specific benefit directly with the plan rather than assuming either answer. Astra's national cash pricing doesn't depend on this either way.
Is it hard to find a primary care doctor in Newark to get evaluated for GLP-1 treatment?
In parts of the city, yes — and it's a new federal finding. HRSA designated "North Newark" a Primary Care shortage area on 1/21/2026 (154,066 residents, a 3,719:1 patient-to-provider ratio against a 3,500:1 goal) and a Mental Health shortage area on 3/11/2026 (86,331 residents). Five separate Newark FQHCs carry their own shortage scores on top of that. Roughly half the city lives inside a primary-care system HRSA has just certified as critically short-staffed — telehealth evaluation is one way to route around that bottleneck.